Media Articles Related to Zytiga (Abiraterone)
Zytiga® (abiraterone acetate) survival data in chemotherapy-na├»ve men with metastatic castration resistant prostate cancer (mCRPC) revealed
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.09.30]
Data from the final analysis of the Phase 3 study COU-AA-302 have shown that Zytiga® (abiraterone acetate) plus low dose prednisolone significantly prolongs overall survival (OS) with a median...
Confirmed: Abiraterone Ups Overall Survival in mCRPC
Source: Medscape Hematology-Oncology Headlines [2014.10.13]
Drs Cora Sternberg and St├ęphane Oudard highlight practice-changing data in prostate cancer, presented at ESMO 2014, including the long-awaited survival results of the COU-AA-302 study.
Published Studies Related to Zytiga (Abiraterone)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone
on pain control and skeletal-related events in patients with metastatic
castration-resistant prostate cancer: exploratory analysis of data from the
COU-AA-301 randomised trial. 
docetaxel chemotherapy... INTERPRETATION: In patients with metastatic castration-resistant prostate cancer
Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. 
Androgen-deprivation therapy is the mainstay of treatment for the management of
advanced prostate carcinoma till transition to castration-resistant prostate
carcinoma (CRPC)... Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org
were made for terms like CRPC and abiraterone.
Effect of abiraterone acetate plus prednisone on the QT interval in patients with
metastatic castration-resistant prostate cancer. 
to assess the effect of AA and abiraterone on the QT interval... CONCLUSIONS: There is no significant effect of AA plus prednisone on the QT/QTc
Clinical Trials Related to Zytiga (Abiraterone)
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate [Recruiting]
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with
Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with
abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same
doses of abiraterone and steroids they were receiving prior to study entry and will be
randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with
abiraterone. Once the best regimen is established in Part A, based on safety and antitumor
activity, patients will be randomized to the selected treatment regimen and dose of AT13387
in combination with abiraterone or AT13387 alone in Part B (Phase 2).
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy [Recruiting]
The United States Food and Drug Administration (FDA) recently approved the oral drug
abiraterone acetate (Zytiga ┬«) in combination with prednisone (a steroid) to treat patients
with metastatic castration-resistant prostate cancer who have received prior docetaxel
(chemotherapy). Degarelix (Firmagon ┬«), a testosterone lowering agent given as a monthly
injection, is FDA approved for the treatment of patients with advanced prostate cancer. The
purpose of this study is to evaluate abiraterone acetate and prednisone in combination with
degarelix as a possible treatment for PSA recurrent prostate cancer as compared to
abiraterone acetate alone and degarelix alone. This will be the first time these drugs will
be used together.
Pharmacodynamic Study of Abiraterone in the Treatment of Advanced Prostate Cancer [Not yet recruiting]
The purpose of this study is to evaluate the molecular effects of Abiraterone acetate and
prednisone on prostate cancer. Participants will take Abiraterone acetate plus prednisone.
While taking these drugs, patients will undergo sampling of cancer: one before treatment and
one during treatment. To measure the body's overall response to Abiraterone acetate, the
study follows patients for Prostate Specific Antigen (PSA) levels, cancer symptoms, and any
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Recruiting]
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate
plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane,
each compared with oral exemestane alone, in postmenopausal women with estrogen
receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after
treatment with letrozole or anastrozole.
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer [Not yet recruiting]
There will be two parts to this clinical research study. The purpose of each part is:
- Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with
a standard dose of abiraterone acetate and prednisone by administering different doses
of BEZ235. This will help to find out what effects, good and/or bad, this combination
has on CRPC.
- Phase 2: This part of the study will measure the treatment effect of the combination of
BEZ235 and abiraterone acetate/prednisone on CRPC.
Reports of Suspected Zytiga (Abiraterone) Side Effects
Prostatic Specific Antigen Increased (55),
Oedema Peripheral (35),
Drug Ineffective (25),
Confusional State (24),
Weight Decreased (24),
Blood Alkaline Phosphatase Increased (22),
Thrombocytopenia (21), more >>